UPC APP 11680/2025

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
—
Action
Procedural application
Category
Withdrawal Applications
Parties: Claimants
Sanofi Mature IP
Sanofi Winthrop Industrie
Sanofi-Aventis France
Sanofi-Aventis GmbH
Sanofi Belgium
Sanofi-Aventis Deutschland GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Reps: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)
Respondents
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Medac Gesellschaft für klinische Spezialpräparate m.b.H.
Reps: Daniel Hoppe (Preu Bohlig & Partner); Alexander Eisenführ (Uexkull + Stolberg)
Division: Munich LD
Judges: Matthias Zigann · Presiding Judge / Judge-Rapporteur
Alima Zana · Legally Qualified Judge
Tobias Pichlmaier · Legally Qualified Judge
Carola Wagner · Technically Qualified Judge
Technology: Pharmaceutical & Medical
Language: —
First decided: Mar 19, 2025

Decisions

2025-03-19
Application Rop 265
Procedural order by Munich Local Division (UPC_CFI_146/2024, 26 March 2025) granting Medac's application to withdraw its third-party access application, ordering deletion of a confidential Sanofi letter that Medac had uploaded without authorisation, imposing the deletion costs on Medac, and issuing a formal warning to Medac's representative for negligent conduct in uploading a privileged document. The court declined to award costs in the R.262(1)(b) application.
Legal issues:Withdrawal of application (R. 265 RoP)Professional conduct / privilege breach (R. 290.2 RoP, Code of Conduct)Deletion of uploaded document (CMS)Costs in R.262(1)(b) proceedings

Documents